Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May 21.
doi: 10.1111/anae.15141. Online ahead of print.

Understanding the COVID-19 Coagulopathy Spectrum

Affiliations
Editorial

Understanding the COVID-19 Coagulopathy Spectrum

J Thachil et al. Anaesthesia. .

Abstract

The SARS-Cov-2 (COVID-19) pandemic has already claimed over 200,000 lives. Quite early on in this pandemic, it was recognised that the virus triggers the immune system leading to a cytokine storm in some severely ill patients [1]. This hyper-responsiveness has been suggested to be the predominant aetiology for clinical deterioration and mortality in patients with this infection [2]. More recently, there have been several reports of increased thrombotic events in these patients [3-6]. From a laboratory perspective, this hypercoagulability is reflected in the marked elevation of the fibrinolytic marker, D-dimer, in almost all hospitalised COVID-19 patients [7]. We must, therefore, ask ourselves what is the link between the extremes of the immune system, presenting as cytokine storm, and the extremes of coagulation, presenting as arterial and venous thromboembolism?

Keywords: COVID-19; coagulation; thrombosis.

Similar articles

See all similar articles

Publication types

LinkOut - more resources

Feedback